| Description | Ximoprofen is a novel anti-inflammatory compound for the study of spondylitis. |
| In vivo | 本研究旨在评估Ximoprofen不同日剂量对活动性强直性脊柱炎患者的疗效。研究持续2周，设置5个平行组：安慰剂组以及Ximoprofen 5 mg、10 mg、20 mg和30 mg日剂量组。治疗反应定义为研究期间疼痛（VAS 100 mm）改善至少50%。研究结束时，Ximoprofen各组的应答者比例（分别为5 mg组54%、10 mg组41%、20 mg组53%、30 mg组56%）均高于安慰剂组（21%）。Ximoprofen的明显剂量相关效应在治疗一周后观察到。该研究1/证实了Ximoprofen 30 mg日剂量的疗效，2/显示了较低剂量下疗效的持续性，3/表明强直性脊柱炎是评估NSAIDs在临床评价早期阶段的一个敏感且相关的人体模型。[1] |
| Synonyms | Ximoprofeno, Ximoprofenum |
| molecular weight | 261.32 |
| Molecular formula | C15H19NO3 |
| CAS | 56187-89-4 |
| Storage | |Powder: -20°C for 3 years | In solvent: -80°C for 1 year |
| Solubility | DMSO: 50 mg/mL (191.34 mM) |
| References | 1. Dougados M, et al. Ximoprofen in ankylosing spondylitis. A double blind placebo controlled dose ranging study. Scand J Rheumatol. 1994;23(5):243-8. 2. Taylor IW, et al. Pharmacokinetics of the anti-inflammatory drug ximoprofen in healthy young and elderly subjects: comparison with elderly rheumatic patients. Br J Clin Pharmacol. 1991 Aug;32(2):242-5. 3. Taylor IW, et al. Pharmacokinetics of the anti-inflammatory drug ximoprofen in healthy subjects and in disease states. Eur J Clin Pharmacol. 1991;40(1):101-6. 4. Morris GR, et al. Determination of ximoprofen and its metabolites in human urine by high-performance liquid chromatography with ultraviolet absorbance detection. J Chromatogr. 1990 Sep 14;530(2):377-85. |